Tech Company Financing Transactions

Crescendo Bioscience Funding Round

Myriad Genetics participated in a $25 million funding round for Crescendo Bioscience. The round was announced by the company on 9/8/2011.

Transaction Overview

Announced On
9/8/2011
Transaction Type
Debt
Amount
$25,000,000
Round
Undisclosed
Proceeds Purpose
The $25 million investment by Myriad Genetics is non-dilutive capital that is structured as long term debt and is accompanied by a three-year option to acquire Crescendo Bioscience for cash at a predetermined multiple of revenue based on the growth rate of Crescendo Bioscience at the time of option exercise. The option allows Crescendo Bioscience to continue to operate independently and may be exercised after Crescendo Bioscience attains a minimum revenue milestone.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
341 Oyster Point Blvd
South San Francisco, CA 94080
USA
Email Address
Not Recorded
Overview
Crescendo Bioscience is developing a broad range of quantitative, objective diagnostic tools to provide Rheumatologists with deeper clinical insights to more effectively manage patients with autoimmune and inflammatory diseases.
Profile
Crescendo Bioscience LinkedIn Company Profile
Social Media
Crescendo Bioscience Company Twitter Account
Company News
Crescendo Bioscience News
Facebook
Crescendo Bioscience on Facebook
YouTube
Crescendo Bioscience on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
William Hagstrom
  William Hagstrom LinkedIn Profile  William Hagstrom Twitter Account  William Hagstrom News  William Hagstrom on Facebook
Chief Information Officer
Alex Bangs
  Alex Bangs LinkedIn Profile  Alex Bangs Twitter Account  Alex Bangs News  Alex Bangs on Facebook
Chief Medical Officer
Oscar Segurado
  Oscar Segurado LinkedIn Profile  Oscar Segurado Twitter Account  Oscar Segurado News  Oscar Segurado on Facebook
Chief Operating Officer
Brian Bertha
  Brian Bertha LinkedIn Profile  Brian Bertha Twitter Account  Brian Bertha News  Brian Bertha on Facebook
VP - Bus. Development
Lucy Lu
  Lucy Lu LinkedIn Profile  Lucy Lu Twitter Account  Lucy Lu News  Lucy Lu on Facebook
VP - Finance
Timothy Henn
  Timothy Henn LinkedIn Profile  Timothy Henn Twitter Account  Timothy Henn News  Timothy Henn on Facebook
VP - Sales
Erik Harris
  Erik Harris LinkedIn Profile  Erik Harris Twitter Account  Erik Harris News  Erik Harris on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/8/2011: Crescendo Bioscience venture capital transaction
Next: 9/8/2011: Wildcat Discovery Technologies venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary